168 related articles for article (PubMed ID: 34412629)
1. Use of proteomics to identify mechanisms of hepatocellular carcinoma with the CYP2D6*10 polymorphism and identification of ANGPTL6 as a new diagnostic and prognostic biomarker.
Hu G; Gao F; Wang G; Fang Y; Guo Y; Zhou J; Gu Y; Zhang C; Gao N; Wen Q; Qiao H
J Transl Med; 2021 Aug; 19(1):359. PubMed ID: 34412629
[TBL] [Abstract][Full Text] [Related]
2. Screening for Lipid-Metabolism-Related Genes and Identifying the Diagnostic Potential of ANGPTL6 for HBV-Related Early-Stage Hepatocellular Carcinoma.
Zuo D; Xiao J; An H; Chen Y; Li J; Yang X; Wang X; Ren L
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36421714
[TBL] [Abstract][Full Text] [Related]
3. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma.
Zhou J; Wen Q; Li SF; Zhang YF; Gao N; Tian X; Fang Y; Gao J; Cui MZ; He XP; Jia LJ; Jin H; Qiao HL
Oncotarget; 2016 Aug; 7(31):50612-50623. PubMed ID: 27203676
[TBL] [Abstract][Full Text] [Related]
4. The POR rs10954732 polymorphism decreases susceptibility to hepatocellular carcinoma and hepsin as a prognostic biomarker correlated with immune infiltration based on proteomics.
Fang Y; Yang H; Hu G; Lu J; Zhou J; Gao N; Gu Y; Zhang C; Qiu J; Guo Y; Zhang Y; Wen Q; Qiao H
J Transl Med; 2022 Feb; 20(1):88. PubMed ID: 35164791
[TBL] [Abstract][Full Text] [Related]
5. Global proteomic profiling in multistep hepatocarcinogenesis and identification of PARP1 as a novel molecular marker in hepatocellular carcinoma.
Xu X; Liu Z; Wang J; Xie H; Li J; Cao J; Zhou L; Zheng S
Oncotarget; 2016 Mar; 7(12):13730-41. PubMed ID: 26883192
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.
Yan P; Huang Z; Mou T; Luo Y; Liu Y; Zhou B; Cao Z; Wu Z
BMC Cancer; 2021 Apr; 21(1):436. PubMed ID: 33879119
[TBL] [Abstract][Full Text] [Related]
7. Angiopoietin-like protein 3 and 4 expression 4 and their serum levels in hepatocellular carcinoma.
El-Shal AS; Zidan HE; Rashad NM; Wadea FM
Cytokine; 2017 Aug; 96():75-86. PubMed ID: 28371666
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic value of lncRNA cancer susceptibility candidate 9 in hepatocellular carcinoma.
Zeng YL; Guo ZY; Su HZ; Zhong FD; Jiang KQ; Yuan GD
World J Gastroenterol; 2019 Dec; 25(48):6902-6915. PubMed ID: 31908394
[TBL] [Abstract][Full Text] [Related]
9. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
[TBL] [Abstract][Full Text] [Related]
10. Development of biomarkers for screening hepatocellular carcinoma using global data mining and multiple reaction monitoring.
Kim H; Kim K; Yu SJ; Jang ES; Yu J; Cho G; Yoon JH; Kim Y
PLoS One; 2013; 8(5):e63468. PubMed ID: 23717429
[TBL] [Abstract][Full Text] [Related]
11. Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma.
Grinchuk OV; Yenamandra SP; Iyer R; Singh M; Lee HK; Lim KH; Chow PK; Kuznetsov VA
Mol Oncol; 2018 Jan; 12(1):89-113. PubMed ID: 29117471
[TBL] [Abstract][Full Text] [Related]
12. ANGPTL6-mediated angiogenesis promotes alpha fetoprotein-producing gastric cancer progression.
Chen E; Tang C; Peng K; Cheng X; Wei Y; Liu T
Pathol Res Pract; 2019 Aug; 215(8):152454. PubMed ID: 31146977
[TBL] [Abstract][Full Text] [Related]
13. Identification of prognostic biomarkers associated with the occurrence of portal vein tumor thrombus in hepatocellular carcinoma.
Lin T; Lin Z; Mai P; Zhang E; Peng L
Aging (Albany NY); 2021 Apr; 13(8):11786-11807. PubMed ID: 33878734
[TBL] [Abstract][Full Text] [Related]
14. Identification of noninvasive diagnostic biomarkers for hepatocellular carcinoma by urinary proteomics.
Zhao Y; Li Y; Liu W; Xing S; Wang D; Chen J; Sun L; Mu J; Liu W; Xing B; Sun W; He F
J Proteomics; 2020 Aug; 225():103780. PubMed ID: 32298775
[TBL] [Abstract][Full Text] [Related]
15. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers.
Agúndez JA; Olivera M; Ladero JM; Rodriguez-Lescure A; Ledesma MC; Diaz-Rubio M; Meyer UA; Benítez J
Pharmacogenetics; 1996 Dec; 6(6):501-12. PubMed ID: 9014199
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
Chen S; Zhao E
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101587. PubMed ID: 33662631
[TBL] [Abstract][Full Text] [Related]
17. Promising key genes associated with tumor microenvironments and prognosis of hepatocellular carcinoma.
Pan L; Fang J; Chen MY; Zhai ST; Zhang B; Jiang ZY; Juengpanich S; Wang YF; Cai XJ
World J Gastroenterol; 2020 Feb; 26(8):789-803. PubMed ID: 32148377
[TBL] [Abstract][Full Text] [Related]
18. Serum small extracellular vesicle-derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma.
Kim SS; Baek GO; Ahn HR; Sung S; Seo CW; Cho HJ; Nam SW; Cheong JY; Eun JW
Mol Oncol; 2020 Oct; 14(10):2646-2659. PubMed ID: 32525601
[TBL] [Abstract][Full Text] [Related]
19. Identification of Potential Hub Genes Related to Diagnosis and Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma via Integrated Bioinformatics Analysis.
Tang Y; Zhang Y; Hu X
Biomed Res Int; 2020; 2020():4251761. PubMed ID: 33376723
[TBL] [Abstract][Full Text] [Related]
20. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
